Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
12/2005
12/13/2005US6974816 Combination for the treatment of endothelial damage
12/13/2005US6974698 Methods for delivering biologically active molecules into cells
12/13/2005US6974695 Complementing cell lines
12/13/2005US6974672 Diagnosing ovavrian and colon tumors via over expression of cathepsin Z (CTSZ) and CD24 gene products; gene therapy; drug screening; antitumor agents; gene expression inhibition
12/13/2005US6974667 Detecting the level of expression in a tissue sample of two or more genes; wherein differential expression of the genes is indicative of liver cancer
12/13/2005US6974589 Neutral-cationic lipid for nucleic acid and drug delivery
12/13/2005US6974571 Isolated stromal cells and methods of using the same
12/13/2005CA2403947C Bir domains of mammalian iap gene family
12/08/2005WO2005116233A2 Composition and method of cancer treatment
12/08/2005WO2005116225A1 Method for introducing and expressing rna in cells
12/08/2005WO2005116224A2 Tetracycline-regulated adeno-associated viral (aav) vectors for gene delivery to the nervous system
12/08/2005WO2005116212A2 Treatment of neurodegenerative disease through intracranial delivery of sirna
12/08/2005WO2005116210A2 Stat6 inhibiting sirna and shrna for use in the treatment of allergic diseases, pathological changes of the respiratory system and cancer
12/08/2005WO2005116207A1 Telomerase-inhibitory ena oligonucleotide
12/08/2005WO2005116204A1 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
12/08/2005WO2005116194A1 Method of culturing myoblst or myoblast-like cell for forming myofiber in vitro
12/08/2005WO2005116192A2 Genetically engineered cells for therapeutic applications
12/08/2005WO2005116045A1 Compositions and processes using sirna, amphipathic compounds and polycations
12/08/2005WO2005115481A2 Nuclease resistant double-stranded ribonucleic acid
12/08/2005WO2005115480A2 Modified protein kinase a-specific oligonucleotides and methods of their use
12/08/2005WO2005115479A2 Peptide conjugated, inosine-substituted antisense oligomer compound and method
12/08/2005WO2005115478A2 Methods and compositions for autism spectrum disorders
12/08/2005WO2005115477A2 Non-natural ribonuclease conjugates as cytotoxic agents
12/08/2005WO2005115476A1 Drug comprising as the active ingredient proliferative vector containing survivin promoter
12/08/2005WO2005115450A1 Compositions comprising demethylating agents as enhancers of immunotherapy for the treatment of chronic infections and neoplastic diseases and methods for treating the same
12/08/2005WO2005115358A2 Intranasal delivery of nucleic acid molecules
12/08/2005WO2005115136A2 Transgenic models of alzheimer’s disease and uses thereof in the treatment of a variety of neurodegenerative diseases
12/08/2005WO2005099771A3 Methods and compositions for treating neuropathic and neurodegenerative conditions
12/08/2005WO2005089411A3 Tissue products from animals lacking functional alpha 1,3 galactosyl transferase
12/08/2005WO2005082080A3 Method to modulate the immune system with a novel guanine nucleotide exchange factor
12/08/2005WO2005079829A3 Method for treating glaucoma
12/08/2005WO2005077412A3 Compositions and methods of use of w-peptides
12/08/2005WO2005068640A3 Modified ksa and uses thereof
12/08/2005WO2005060721A3 Manipulation of rna interference through modulation of armitage activity
12/08/2005WO2005054432A3 Gene transfer for regulating smooth muscle tone
12/08/2005WO2005018534A3 Methods and compositions for rna interference
12/08/2005WO2004058042A3 Methods for evaluating genetic susceptibility and therapy for chronic inflammatory diseases
12/08/2005US20050272915 Skrp, astray, string, vacm associated with metabolic control
12/08/2005US20050272684 Breast cancer resistance protein (BCRP) and the DNA which encodes it
12/08/2005US20050272683 Antisense oligonucleotides against thymidylate synthase
12/08/2005US20050272682 SiRNA targeting PI3K signal transduction pathway and siRNA-based therapy
12/08/2005US20050272681 Ribosome structure and protein synthesis inhibitors
12/08/2005US20050272678 BMP-6 estrogen responsive element and methods of use thereof
12/08/2005US20050272677 Delivery of a substance to a pre-determined site
12/08/2005US20050272650 Materials and methods for treatment of inflammatory and cell proliferation disorders
12/08/2005US20050272633 Derivatives of the nf-kappab inducing enzyme, their preparation and use
12/08/2005US20050272156 Utilizes one or more sets of electrodes spaced to hold surface tension of sample receiving pulses; for gene discovery/therapy/tissue engineering
12/08/2005US20050272154 Alkylation of a nucleic acid at the N7 position of a guanine nucleotide; improved genetic transduction; maintained genetic expressibility; gene therapy
12/08/2005US20050272149 Therapeutic delivery of adenosine into a tissue
12/08/2005US20050272148 Method of collecting placental stem cells
12/08/2005US20050272091 Neisserial protein for use in diagnosis, prevention and treatment of microorganismal infection
12/08/2005US20050272090 Nucleic acid binding of multi-zinc finger transcription factors
12/08/2005US20050272050 Receptor protein for identifying modulators to treat and prevent inflammatory, antherosclerotic and cancer disorders; wound healing agents
12/08/2005US20050272040 Method for increasing synaptic growth or plasticity
12/08/2005US20050271733 Particle delivery techniques
12/08/2005US20050271696 Medical device having a surface including a biologically active agent therein, and methods
12/08/2005US20050271688 Modified vaccinia ankara virus variant
12/08/2005US20050271687 Retrovirus-like particles made non-infectious by a plurality of mutations
12/08/2005US20050271670 Treatments for cancer
12/08/2005US20050271668 Janus family kinases and identification of immune modulators
12/08/2005US20050271667 Identification of a novel endothelial-derived gene EG-1
12/08/2005US20050271655 Nogo receptor antagonists
12/08/2005US20050271651 Inhibition of bright function as a treatment for excessive immunoglobulin production
12/08/2005US20050271639 Genetically engineered cells for therapeutic applications
12/08/2005US20050271638 BMP pathway methods and compositions
12/08/2005US20050271637 BMP-2 estrogen responsive element and methods of using the same
12/08/2005US20050271636 Diagnostic and therapeutic uses for prox 1
12/08/2005US20050271632 Methods of modulating hair growth
12/08/2005US20050271630 Method for treating cancer
12/08/2005US20050271628 Negative-sense RNA virus vector for nerve cell
12/08/2005US20050271627 Calbindin-D28K protection against glucocorticoid induced cell death
12/08/2005US20050271626 Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
12/08/2005US20050271625 RAAV-neprilysin compositions and methods of use
12/08/2005US20050271624 Use of apoptosis inducing agents in the treatment of (auto) immune diseases
12/08/2005US20050271623 Reduction of dermal scarring
12/08/2005US20050271622 Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
12/08/2005US20050271621 Ablated slam-dependent entry
12/08/2005US20050271620 Herpes simplex virus complex
12/08/2005DE10085485B4 Verfahren zur Detektion des Mutationsgens dspp des hereditären opalisierenden Dentins Method for the detection of the mutation gene DSPP of hereditary opalescent dentin
12/08/2005CA2568013A1 Nuclease resistant double-stranded ribonucleic acid
12/08/2005CA2566286A1 Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
12/08/2005CA2565103A1 Peptide conjugated, inosine-substituted antisense oligomer compound and method
12/08/2005CA2565098A1 Treatment of neurodegenerative disease through intracranial delivery of sirna
12/08/2005CA2563926A1 Transgenic models of alzheimer's disease and uses thereof in the treatment of a variety of neurodegenerative diseases
12/08/2005CA2558871A1 Composition and method of cancer treatment
12/07/2005EP1602669A1 Antibody against tumor specific antigen as target
12/07/2005EP1602666A1 Novel protein and its dna
12/07/2005EP1602380A1 Preventive/remedy for diseases in upper digestive tract
12/07/2005EP1601789A2 Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
12/07/2005EP1601782A2 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
12/07/2005EP1601776A2 Expression vectors comprising the mcmv ie2 promoter
12/07/2005EP1601772A1 Modified tert promoter with enhanced tumor-specificity and strength and recombinant vector comprising the same
12/07/2005EP1601767A2 USE OF ANTISENSE OLIGONUCLEOTIDES OR siRNA TO SUPPRESS EXPRESSION OF EIF-5A1
12/07/2005EP1601696A1 Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
12/07/2005EP1601695A1 Mcam inhibitors
12/07/2005EP1601693A2 Novel compositions and methods for the treatment of immune related disease
12/07/2005EP1601682A2 Compositions and methods for diagnosing and treating prostate cancer
12/07/2005EP1601374A2 Compositions and methods for diagnosing and treating an inflammation
12/07/2005EP1601333A2 Novel insertion sites in pox vectors
12/07/2005EP1601331A2 Il-2 transmembrane constructs
1 ... 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 ... 870